PMID- 18204965
OWN - NLM
STAT- MEDLINE
DCOM- 20080902
LR  - 20211020
IS  - 0271-9142 (Print)
IS  - 0271-9142 (Linking)
VI  - 28
IP  - 3
DP  - 2008 May
TI  - Modified donor lymphocyte infusion after HLA-mismatched/haploidentical T 
      cell-replete hematopoietic stem cell transplantation for prophylaxis of relapse 
      of leukemia in patients with advanced leukemia.
PG  - 276-83
LID - 10.1007/s10875-007-9166-z [doi]
AB  - We evaluated the safety and efficacy of donor lymphocyte infusion (DLI) with 
      granulocyte colony-stimulating factor priming and short-term immunosuppressive 
      agents for prophylaxis of relapse in patients with advanced leukemia after human 
      leukocyte antigen (HLA)-mismatched T cell-replete hematopoietic stem cell 
      transplantation (HCT). Twenty-nine patients received prophylactic DLI at a median 
      75 (33-120) days after HCT. Acute graft-vs-host disease (GVHD) grades 3-4 
      occurred in six patients, and all cases were controlled. Eleven patients were 
      alive and relapse-free with a probability of leukemia-free survival (LFS) of 37.3 
      +/- 9.6% at 3 years. Chronic GVHD was associated with a lower relapse rate and 
      higher probability of LFS. Prophylactic-modified DLI is feasible in patients with 
      advanced leukemia to prevent relapse after HLA-mismatched HCT.
FAU - Huang, Xiao-Jun
AU  - Huang XJ
AD  - Institute of Hematology, People's Hospital, Peking University, no. 11 Xizhimen 
      South Street, 100044 Beijing, People's Republic of China. xjhrm@medmail.com.cn
FAU - Liu, Dai-Hong
AU  - Liu DH
FAU - Liu, Kai-Yan
AU  - Liu KY
FAU - Xu, Lan-Ping
AU  - Xu LP
FAU - Chen, Yu-Hong
AU  - Chen YH
FAU - Wang, Yu
AU  - Wang Y
FAU - Han, Wei
AU  - Han W
FAU - Chen, Huan
AU  - Chen H
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - J Clin Immunol
JT  - Journal of clinical immunology
JID - 8102137
RN  - 0 (HLA Antigens)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Blood Transfusion, Autologous
MH  - Disease-Free Survival
MH  - Female
MH  - Graft vs Host Disease
MH  - HLA Antigens/*genetics
MH  - *Hematopoietic Stem Cell Transplantation
MH  - *Histocompatibility Testing
MH  - Humans
MH  - Leukemia, Myeloid, Acute/immunology/*prevention & control
MH  - Lymphocyte Depletion
MH  - *Lymphocyte Transfusion
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local/*prevention & control
MH  - T-Lymphocytes/immunology/*transplantation
EDAT- 2008/01/22 09:00
MHDA- 2008/09/03 09:00
CRDT- 2008/01/22 09:00
PHST- 2007/11/25 00:00 [received]
PHST- 2007/12/27 00:00 [accepted]
PHST- 2008/01/22 09:00 [pubmed]
PHST- 2008/09/03 09:00 [medline]
PHST- 2008/01/22 09:00 [entrez]
AID - 10.1007/s10875-007-9166-z [doi]
PST - ppublish
SO  - J Clin Immunol. 2008 May;28(3):276-83. doi: 10.1007/s10875-007-9166-z.